- Home
- XAIR
XAIR
Beyond Air Inc.
as 11-15-2024 4:00pm EST
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | GARDEN CITY |
| Market Cap: | 34.7M | IPO Year: | N/A |
| Target Price: | $3.67 | AVG Volume (30 days): | 636.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.30 - $2.36 | Next Earning Date: | 11-11-2024 |
| Revenue: | $2,342,000 | Revenue Growth: | 685.91% |
| Revenue Growth (this year): | 640.47% | Revenue Growth (next year): | 286.81% |
Stock Insider Trading Activity of Beyond Air Inc. (XAIR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lisi Steven A. | XAIR | CEO and Chairman of the Board | Sep 26 '24 | Buy | $0.50 | 1,476,626 | $744,662.49 | 3,249,411 | |
| Carey Robert | XAIR | Director | Sep 26 '24 | Buy | $0.50 | 1,476,626 | $744,662.49 | 1,476,626 |
Latest Beyond Air Inc. News
XAIR Breaking Stock News: Dive into XAIR Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
6 days ago
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
6 days ago
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
GuruFocus.com
9 days ago
Beyond Air Inc (XAIR) Q2 2025 Earnings Report Preview: What To Expect
GlobeNewswire
19 days ago
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast
GlobeNewswire
a month ago
Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire
2 months ago
Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks
TipRanks
2 months ago
Beyond Air to sell 40.39M shares at 51c in private placement
Compare XAIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XAIR Beyond Air Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.